FindTrial
Sign In

Efficacy of L-menthol(MINCLEA®) as an antispasmodic during endoscopic retrograde cholangiopancreatography(ERCP)

Efficacy of L-menthol(MINCLEA®) as an antispasmodic during endoscopic retrograde cholangiopancreatography(ERCP) - Efficacy of L-menthol during endoscopic retrograde cholangiopancreatography(ERCP)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000008008
Enrollment
100
Registered
2012-05-22
Start date
2012-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

biliary and pancreatic disease

Interventions

Continuous 50 patients undergo ERCP with 1mg of glucagon(Glucagon G Novo, JAN code:4987028509318) injected intravenously. Continuous 50 patients undergo ERCP with 20ml of 0.8% L-menthol(MINCLEA,JAN co

Sponsors

Kyoto Second Red Cross Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: the patients with indication of ERCP

Exclusion criteria

Exclusion criteria: 1. the emergency patients 2. the patients with bad general conditions 3. the patients judged inappropriate by their doctors 4. contraindication of glucagon or L-menthol

Design outcomes

Primary

MeasureTime frame
the proportion of subjects with antiperistaltic effect—

Secondary

MeasureTime frame
1. the proportion of subjects who finished the procedure without additional antispasmodic agents 2. complications 3. the interval from administration of antispasmodic agents to success of cannulation (except the subjects of post-sphincterotomy)—

Countries

Japan

Contacts

Public ContactHideaki Kawabata

Kyoto Second Red Cross Hospital Gastroenterology

kawabatah@kyoto2.jrc.or.jp075-231-5171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026